BUY Glenmark Pharmaceuticals — AMIT SETH, 29 Sept 2026

BUYGlenmark Pharmaceuticals

Glenmark Pharmaceuticals share price target & all analyst calls

byAmit SethHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via CNBC Awaaz.

Entry₹2,391Inferred

Target₹2,450

Total upside +2.47%

Stop loss₹2,340-2.13% risk

CMP₹2,334.76h ago

Active-2.35%+4.94%upside left 14d left

Follow Amit Seth for new calls(30% target hit, 135 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 167 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Sept, 11:03 pm IST

11 supporting2 neutral2 opposing

Supports the BUY call (11)

Glenmark Pharma FY26 PAT Rises 30.1% to ₹13,620 Million; Q4 EBITDA Jumps to ₹9.4b

NewsGoogle News·27 Sept · 2d ago

Glenmark Pharma gets EIR for Goa facility from US FDA

NewsGoogle News·23 Sept · 1w ago

Glenmark Receives US FDA Inspection Report For Goa Facility; Shares Rise 0.28%

NewsGoogle News·23 Sept · 1w ago

Glenmark Pharmaceuticals trades higher on getting EIR with VAI status for Goa facility

NewsGoogle News·23 Sept · 1w ago

Glenmark Pharmaceuticals' Goa facility received an Establishment Inspection Report (EIS) from the U.S. FDA with a Voluntary Action Indicated (VAI) classification, suggesting no major compliance issues

BSE · Company Update·23 Sept · 1w ago

Neutral / worth noting (2)

Glenmark Pharmaceuticals (NSE: GLENMARK) U.S. FDA Compliance Update for Goa Facility

NewsGoogle News·23 Sept · 1w ago

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·23 Sept · 1w ago

Weighs against the BUY call (2)

MACD below its signal line — bearish momentum

Technicals · macd·30 Sept · today

Past week's volume 1.6× the 30-day average

Technicals · volume·30 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.